JP2018512062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512062A5 JP2018512062A5 JP2017548855A JP2017548855A JP2018512062A5 JP 2018512062 A5 JP2018512062 A5 JP 2018512062A5 JP 2017548855 A JP2017548855 A JP 2017548855A JP 2017548855 A JP2017548855 A JP 2017548855A JP 2018512062 A5 JP2018512062 A5 JP 2018512062A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- aryl
- tetrahydroimidazo
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000000623 heterocyclic group Chemical group 0.000 claims 34
- -1 -OH Chemical group 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000002950 monocyclic group Chemical group 0.000 claims 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- LRSSUODUVVLJMO-UHFFFAOYSA-N 2-[4-[3-[2-(difluoromethoxy)phenyl]-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraen-12-yl]phenyl]-5-methyl-1,3,4-oxadiazole Chemical compound CC1=NN=C(O1)C1=CC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)F LRSSUODUVVLJMO-UHFFFAOYSA-N 0.000 claims 2
- LIAYRLHOEYLYRD-UHFFFAOYSA-N 2-[4-[3-[2-(difluoromethoxy)phenyl]-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraen-12-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)F LIAYRLHOEYLYRD-UHFFFAOYSA-N 0.000 claims 2
- BXEVCQBRIJKBGK-UHFFFAOYSA-N 2-[5-[3-[2-(trifluoromethoxy)phenyl]-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=NC=C(C=N1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)(F)F BXEVCQBRIJKBGK-UHFFFAOYSA-N 0.000 claims 2
- NEYWZSZKGWQPIT-UHFFFAOYSA-N 3-(2,3-dimethylphenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC(C)=C1C NEYWZSZKGWQPIT-UHFFFAOYSA-N 0.000 claims 2
- SSOYJIBODDUEBN-UHFFFAOYSA-N 3-(2,4-dimethylphenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=C(C)C=C1C SSOYJIBODDUEBN-UHFFFAOYSA-N 0.000 claims 2
- SJYAUOSFCWKCMA-UHFFFAOYSA-N 3-(2,5-dimethylphenyl)-11-methyl-12-(1-methylpyrazol-4-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound CN1C=C(C=N1)C1=CN2C(C=C1C)=NC1=C2N(CCC1)C1=CC(C)=CC=C1C SJYAUOSFCWKCMA-UHFFFAOYSA-N 0.000 claims 2
- ISNVPEHTFMANHQ-UHFFFAOYSA-N 3-(2,5-dimethylphenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC(C)=CC=C1C ISNVPEHTFMANHQ-UHFFFAOYSA-N 0.000 claims 2
- YELUGHHDAGMPFR-UHFFFAOYSA-N 3-(2,5-dimethylphenyl)-6-methyl-12-(1-methylpyrazol-4-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound CC1CCN(C2=C1N=C1C=CC(=CN21)C1=CN(C)N=C1)C1=CC(C)=CC=C1C YELUGHHDAGMPFR-UHFFFAOYSA-N 0.000 claims 2
- DXBLRWOOVQWASI-UHFFFAOYSA-N 3-(2-chlorophenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1Cl DXBLRWOOVQWASI-UHFFFAOYSA-N 0.000 claims 2
- WSZVUMRAHWUBML-UHFFFAOYSA-N 3-(4-fluoro-2-methylphenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=C(F)C=C1C WSZVUMRAHWUBML-UHFFFAOYSA-N 0.000 claims 2
- QMJSYAYVXHPGHF-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC(Cl)=CC=C1C QMJSYAYVXHPGHF-UHFFFAOYSA-N 0.000 claims 2
- OBNJCHVJXDESNR-UHFFFAOYSA-N 3-[2-(difluoromethoxy)-5-methylphenyl]-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC(C)=CC=C1OC(F)F OBNJCHVJXDESNR-UHFFFAOYSA-N 0.000 claims 2
- YUJVHZBMQPZPBW-UHFFFAOYSA-N 3-[2-(difluoromethoxy)phenyl]-11-methyl-12-(1-methylpyrazol-4-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound CN1C=C(C=N1)C1=CN2C(C=C1C)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)F YUJVHZBMQPZPBW-UHFFFAOYSA-N 0.000 claims 2
- WAKBDVCYVKBZOR-UHFFFAOYSA-N 3-[2-(difluoromethoxy)phenyl]-12-(1-methylpyrazol-4-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound CN1C=C(C=N1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)F WAKBDVCYVKBZOR-UHFFFAOYSA-N 0.000 claims 2
- YJHNEWLMWIYRLL-UHFFFAOYSA-N 3-[2-(difluoromethoxy)phenyl]-12-(6-methoxypyridin-3-yl)-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraene Chemical compound COC1=NC=C(C=C1)C1=CN2C(C=C1)=NC1=C2N(CCC1)C1=CC=CC=C1OC(F)F YJHNEWLMWIYRLL-UHFFFAOYSA-N 0.000 claims 2
- CMRXGVMEQDEAGO-UHFFFAOYSA-N 4-[5-[3-[2-(difluoromethoxy)-5-methylphenyl]-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraen-12-yl]pyrimidin-2-yl]morpholine Chemical compound CC1=CC=C(OC(F)F)C(=C1)N1CCCC2=C1N1C=C(C=CC1=N2)C1=CN=C(N=C1)N1CCOCC1 CMRXGVMEQDEAGO-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- SGNASRIYHOLKCO-UHFFFAOYSA-N [5-[3-(2,5-dimethylphenyl)-6-methyl-1,3,8-triazatricyclo[7.4.0.02,7]trideca-2(7),8,10,12-tetraen-12-yl]pyridin-2-yl]methanol Chemical compound CC1CCN(C2=C1N=C1C=CC(=CN21)C1=CN=C(CO)C=C1)C1=CC(C)=CC=C1C SGNASRIYHOLKCO-UHFFFAOYSA-N 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134800P | 2015-03-18 | 2015-03-18 | |
| US62/134,800 | 2015-03-18 | ||
| PCT/US2016/022742 WO2016149439A1 (en) | 2015-03-18 | 2016-03-17 | Heterocyclic compounds useful as inhibitors of tnf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512062A JP2018512062A (ja) | 2018-05-10 |
| JP2018512062A5 true JP2018512062A5 (cg-RX-API-DMAC10.html) | 2019-04-25 |
| JP6779899B2 JP6779899B2 (ja) | 2020-11-04 |
Family
ID=55640934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548855A Active JP6779899B2 (ja) | 2015-03-18 | 2016-03-17 | Ｔｎｆ阻害剤として有用なヘテロ環式化合物 |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6793658B2 (ja) | 2015-03-18 | 2020-12-02 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
| US10189840B2 (en) | 2015-03-18 | 2019-01-29 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CA2994703A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| DE69814049T2 (de) | 1997-02-25 | 2004-02-19 | The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| CN1633434A (zh) | 2002-01-31 | 2005-06-29 | 第一制药株式会社 | 咪唑并[1,2－a]吡啶衍生物 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| WO2008072682A1 (ja) * | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| BR112014030940B1 (pt) | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
| MX2015005375A (es) * | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| WO2014080241A1 (en) * | 2012-11-21 | 2014-05-30 | Piramal Enterprises Limited | Imidazopyridine compounds and uses thereof |
| WO2015008611A1 (ja) | 2013-07-18 | 2015-01-22 | 株式会社 村田製作所 | 積層型インダクタ素子の製造方法 |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| US9920052B2 (en) | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6483697B2 (ja) | 2013-12-09 | 2019-03-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体 |
| ES2980464T3 (es) | 2014-10-06 | 2024-10-01 | Signal Pharm Llc | Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos |
| US10189840B2 (en) | 2015-03-18 | 2019-01-29 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| JP6793658B2 (ja) | 2015-03-18 | 2020-12-02 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
-
2016
- 2016-03-17 WO PCT/US2016/022742 patent/WO2016149439A1/en not_active Ceased
- 2016-03-17 CN CN201680026732.5A patent/CN107567450B/zh active Active
- 2016-03-17 AU AU2016233202A patent/AU2016233202A1/en not_active Abandoned
- 2016-03-17 MX MX2017011577A patent/MX2017011577A/es unknown
- 2016-03-17 SG SG11201707473VA patent/SG11201707473VA/en unknown
- 2016-03-17 CA CA2980161A patent/CA2980161A1/en not_active Abandoned
- 2016-03-17 ES ES16712647T patent/ES2803650T3/es active Active
- 2016-03-17 BR BR112017019605A patent/BR112017019605A2/pt not_active Application Discontinuation
- 2016-03-17 EP EP16712647.3A patent/EP3271362B1/en active Active
- 2016-03-17 US US15/558,724 patent/US10112944B2/en active Active
- 2016-03-17 EA EA201792054A patent/EA201792054A1/ru unknown
- 2016-03-17 KR KR1020177029451A patent/KR102696304B1/ko active Active
- 2016-03-17 JP JP2017548855A patent/JP6779899B2/ja active Active
-
2017
- 2017-09-11 IL IL254430A patent/IL254430A0/en unknown